CAS 174022-42-5|Bevirimat

Introduction：Basic information about CAS 174022-42-5|Bevirimat, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Bevirimat BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	Bevirimat
CAS Number	174022-42-5	Molecular Weight	584.826
Density	1.1±0.1 g/cm3	Boiling Point	662.7±40.0 °C at 760 mmHg
Molecular Formula	C₃₆H₅₆O₆	Melting Point	/
MSDS	/	Flash Point	197.7±20.8 °C

Names

Name	bevirimat
Synonym	More Synonyms

Bevirimat BiologicalActivity

Description	Bevirimat(YK FH312; FH11327; MPC-4326) is an anti-HIV drug derived from a betulinic acid-like compound; is believed to inhibit HIV by a novel mechanism, so-called maturation inhibition.IC50 value:Target: Anti-HIVLike protease inhibitors, bevirimat and other maturation inhibitors interfere with protease processing of newly translated HIV polyprotein precursor, called gag. Bevirimat prevents this viral replication by specifically inhibiting cleavage of the capsid protein (CA) from the SP1 spacer protein.
Related Catalog	Signaling Pathways >>Anti-infection >>HIVResearch Areas >>InfectionNatural Products >>Terpenoids and Glycosides
References	[1]. Smith PF, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81. [2]. Salzwedel K, et al. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev. 2007 Jul-Sep;9(3):162-72. [3]. Martin DE, et al. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.

Description

Bevirimat(YK FH312; FH11327; MPC-4326) is an anti-HIV drug derived from a betulinic acid-like compound; is believed to inhibit HIV by a novel mechanism, so-called maturation inhibition.IC50 value:Target: Anti-HIVLike protease inhibitors, bevirimat and other maturation inhibitors interfere with protease processing of newly translated HIV polyprotein precursor, called gag. Bevirimat prevents this viral replication by specifically inhibiting cleavage of the capsid protein (CA) from the SP1 spacer protein.

Related Catalog

Signaling Pathways >>Anti-infection >>HIVResearch Areas >>InfectionNatural Products >>Terpenoids and Glycosides

References

[1]. Smith PF, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81.

[2]. Salzwedel K, et al. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev. 2007 Jul-Sep;9(3):162-72.

[3]. Martin DE, et al. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.

Chemical & Physical Properties

Density	1.1±0.1 g/cm3
Boiling Point	662.7±40.0 °C at 760 mmHg
Molecular Formula	C₃₆H₅₆O₆
Molecular Weight	584.826
Flash Point	197.7±20.8 °C
Exact Mass	584.407715
PSA	100.90000
LogP	10.15
Vapour Pressure	0.0±4.3 mmHg at 25°C
Index of Refraction	1.548
InChIKey	YJEJKUQEXFSVCJ-WRFMNRASSA-N
SMILES	C=C(C)C1CCC2(C(=O)O)CCC3(C)C(CCC4C5(C)CCC(OC(=O)CC(C)(C)C(=O)O)C(C)(C)C5CCC43C)C12
Storage condition	-20°C

Synonyms

DSB

UNII-S125DW66N8

3-O-(3',3'-dimethylsuccinyl)betulinic acid

YK FH312

YK-FH312

PA-457

BVM

(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-(3-carboxy-3-methylbutanoyl)oxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid

Bevirimat

Butanedioic acid, 2,2-dimethyl-, 4-[(3β)-28-hydroxy-28-oxolup-20(29)-en-3-yl] ester

(3β)-3-[(3-Carboxy-3-methylbutanoyl)oxy]lup-20(29)-en-28-oic acid

Recommended......